Semaglutide at BMI 25: Where Does the Licensed Threshold Actually Sit?

You've checked your BMI and it's 25, here's what the licence actually says

Imagine you've done the calculation, got 25.0, and wondered whether that puts you in range for semaglutide. It doesn't, at least not under the terms of the UK marketing authorisation for Wegovy. The licensed indication, confirmed by the MHRA, is weight management in adults with a BMI of 30 or above, or a BMI of 27 to 29.9 when the person has at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. A BMI of 25 is defined clinically as the top end of the healthy range, meaning neither threshold applies.

That's a genuinely frustrating place to be if you're carrying extra weight and experiencing real health consequences. It is worth knowing, though, that BMI as a standalone figure has well-documented limitations as a health measure. It says nothing about where fat is distributed, muscle mass, metabolic risk or how a person feels day to day. The role BMI plays in semaglutide eligibility is better understood as a starting filter, not a complete clinical picture. A prescriber looks at the whole person, and a BMI of 25 means the starting filter rules out Wegovy before that broader review begins.

The NHS BMI calculator can help you confirm your number precisely, since even small differences (25.0 versus 27.1) carry significant weight in this context. The NHS BMI tool takes height and weight and returns your BMI category, which is a useful first step before any consultation.

The ethnic-background adjustment doesn't bring BMI 25 into range

NICE guidance on tirzepatide and semaglutide acknowledges that standard BMI thresholds can underestimate health risk in people from some ethnic backgrounds. For South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds, NICE recommends thresholds that are 2.5 kg/m² lower than the standard values. In practice, that shifts the "with a qualifying condition" threshold from 27 to 24.5 for those groups.

If you're in one of those groups and your BMI is 25, you might read that and think you've found a route in. The situation is more nuanced. The 24.5 figure comes from NICE's commissioning recommendations for NHS services, which operate under specific criteria. For private prescribing, the licensed threshold remains 27 (or 24.5 under the ethnic-background adjustment) with a qualifying condition present, so at BMI 25 with a qualifying condition, there may be a clinical conversation worth having. At BMI 25 without any weight-related health conditions, the licence does not provide a basis for prescribing regardless of background.

This is exactly the kind of nuance that a prescriber is there to work through with you. Who can take semaglutide in the UK covers the full eligibility picture, including what counts as a qualifying condition and how the ethnic-background adjustment applies in practice.

What to consider if your BMI is close to the threshold

A BMI of 25 sits at the boundary of the healthy and overweight categories. If yours has recently tipped just above or below 25, it's possible that a careful measurement (ideally in consistent conditions) places you at 26 or 27. Small differences here genuinely matter. For anyone in that borderline zone, what semaglutide eligibility looks like at BMI 26 is worth reading before drawing conclusions, as that threshold is closer to the licence boundary.

It's also worth thinking about what else is going on health-wise. High blood pressure, raised blood sugar in the pre-diabetes range, elevated triglycerides, interrupted sleep from sleep apnoea, these are conditions that can coexist with a BMI of 25, and they change the calculation if your BMI is at 27 or above. If none of those apply and your BMI genuinely is 25, semaglutide is not currently licensed for your situation. That's a hard line, and a legitimate prescriber will tell you the same.

For anyone weighing up whether a private consultation makes sense, understanding the full range of weight-loss treatments available (including what the eligibility criteria look like across options) is a good starting point. Our prescribers also cover which patients are and aren't suitable for semaglutide in detail, which may help you come into any consultation with a clearer picture of your own situation.

What happens next if semaglutide isn't the right fit right now

Hearing that a specific medicine isn't licensed for you can feel like a door closing. Many people tell us they've spent time researching options and found this kind of answer deflating. It's a reasonable reaction, and the honest response is that the licensing threshold exists for clinical reasons, the trials that established semaglutide's risk-benefit profile were conducted in people with higher BMIs, so extending prescribing below those thresholds would step outside the evidence base.

That doesn't mean there's nothing to do. If weight and health are on your mind, a GP conversation about lifestyle support, or a review of any underlying conditions that might shift your eligibility picture in future, is worth having. If your BMI moves above 27 and a qualifying condition is present, the picture changes. How Wegovy works and what the evidence says gives a thorough grounding in the medicine for when the time is right, and the BMI criteria for Wegovy explains what the thresholds look like across the full eligibility range.

Semaglutide is reviewed by NICE under technology appraisal TA875, which sets out the evidence and conditions under which it is recommended. Reading that gives a clear sense of the clinical reasoning behind the eligibility criteria, and why they're unlikely to shift significantly in the near term for people at BMI 25 without comorbidities.